Machine signal
Active cluster buy — 3 distinct insiders, $120.4K, window ends Sep 15, 2026.
Figures computed from official regulatory filings — .
Analysttarget 47.5 USD (+1098%) · consensus 3/5 · 0 buy · 1 hold · 0 sell
Ownershipinsiders 15.99% · institutions 25.53% · short 4.2% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Cytosorbents Corp only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
83 buys111 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Capponi Vincenttrack record | Buy | $1.6K | conv 36First in 12mo |
| SEC |
| Chan Phillip P.track record | Buy | $22.6K | conv 40Cluster | SEC |
| Sobel Alan D.track record | Buy | $11.6K | conv 49ClusterFirst in 12mo | SEC |
| Sobel Alan D.track record | Buy | $601 | conv 43ClusterFirst in 12mo | SEC |
| Capponi Vincenttrack record | Buy | $10.9K | conv 40First in 12mo | SEC |
| Sobel Alan D.track record | Buy | $3K | conv 44ClusterFirst in 12mo | SEC |
| Chan Phillip P.track record | Buy | $70K | conv 56 | SEC |
| MARIANI PETER Jtrack record | Buy | $44K | conv 82Unusual sizeFirst in 12mo | SEC |
| Chan Phillip P.track record | Buy | $4.4K | conv 40 | SEC |
| Chan Phillip P.track record | Buy | $100.5K | conv 79Unusual sizeFirst in 12mo | SEC |
| Chan Phillip P.track record | Award | $64K | SEC |
| BATOR MICHAEL G.track record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| MARIANI PETER Jtrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sobel Alan D.track record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Chan Phillip P.track record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kim Jiny | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Deliargyris Efthymios | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Chan Phillip P.track record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Capponi Vincenttrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Deliargyris Efthymios | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Jones Edward Raymondtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| MARIANI PETER Jtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Capponi Vincenttrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BATOR MICHAEL G.track record | Other | $11.3K | SEC |
| BATOR MICHAEL G.track record | OtherD (derivative) | $17.9K | SEC |